首页> 外文期刊>European Journal of Pharmacology: An International Journal >Peroxisome proliferator-activated receptor-alpha activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.
【24h】

Peroxisome proliferator-activated receptor-alpha activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.

机译:过氧化物酶体增殖物激活的受体-α激活减弱了3-硝基丙酸诱导的大鼠行为和生化改变:可能的神经保护机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Peroxisome proliferators activated receptor is regarded as potential therapeutic targets to control various neurodegenerative disorders. However, none of the study has elucidated its effect in the treatment of Huntington's disease. We explored whether peroxisome proliferators activated receptor-alpha agonist may attenuate various behavioral and biochemical alterations induced by systemic administration of 3-nitropropionic acid (3-NP), an accepted experimental animal model of Huntington's disease phenotype. Intraperitoneal administration of 3-NP (20mg/kg., i.p.) for 4days in rats produced hypolocomotion, muscle incoordination, and cognitive dysfunction. Daily treatment with fenofibrate (100 or 200mg/kg., p.o.), 30min prior to 3-NP administration for a total of 4days, significantly improved the 3-NP induced motor and cognitive impairment. Biochemical analysis revealed that systemic 3-NP administration significantly increased oxidative and nitrosative stress (increase lipid peroxidation, protein carbonyls and nitrite level), lactate dehydrogenase activity whereas, decreased the activities of catalase, superoxide dismutase, reduced glutathione, and succinate dehydrogenase. Fenofibrate treatment significantly attenuated oxidative damage, cytokines and improved mitochondrial complexes enzyme activity in brain. In the present study, MK886, a selective inhibitor of peroxisome proliferators activated receptor-alpha was employed to elucidate the beneficial effect through either receptor dependent or receptor independent neuroprotective mechanisms. Administration of MK886 (1mg/kg, i.p.) prior to fenofibrate (200mg/kg, p.o.) abolished the effect of fenofibrate. The results showed that receptor dependent neuroprotective effects of fenofibrate in 3-NP administered rats provide a new evidence for a role of PPAR-alpha activation in neuroprotection that is attributed by modulating oxidative stress and inflammation.
机译:过氧化物酶体增殖物激活受体被认为是控制各种神经退行性疾病的潜在治疗靶标。但是,没有一项研究阐明其在亨廷顿氏病治疗中的作用。我们探讨了过氧化物酶体增殖物激活的受体-α激动剂是否可以减弱由系统施用3-硝基丙酸(3-NP)(亨廷顿氏病表型的一种公认的实验动物模型)引起的各种行为和生化改变。大鼠腹腔内给予3-NP(20mg / kg。,i.p.)4天,导致运动不足,肌肉不协调和认知功能障碍。每天服用非诺贝特(100或200mg / kg。,p.o.),在3-NP给药前30分钟共4天,可显着改善3-NP诱导的运动和认知障碍。生化分析表明,全身性3-NP给药显着增加了氧化和亚硝化应激(增加了脂质过氧化,蛋白质羰基和亚硝酸盐水平),乳酸脱氢酶活性,而降低了过氧化氢酶,超氧化物歧化酶,减少了谷胱甘肽和琥珀酸脱氢酶的活性。非诺贝特治疗可显着减轻大脑的氧化损伤,细胞因子并改善线粒体复合物的酶活性。在本研究中,采用过氧化物酶体增殖物的选择性抑制剂激活受体αMK886来阐明通过受体依赖性或受体依赖性神经保护机制的有益作用。非诺贝特(200mg / kg,口服)之前给予MK886(1mg / kg,腹膜内)消除了非诺贝特的作用。结果表明非诺贝特在3-NP给药大鼠中的受体依赖性神经保护作用为PPAR-α激活在神经保护中的作用提供了新证据,这是由于调节氧化应激和炎症所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号